Introduction
Chronic kidney disease (CKD) is a growing global public health problem (1) . However, there is paucity of sensitive biomarkers to detect early CKD and there are few specific and effective strategies to retard CKD progression to end-stage renal disease (ESRD). Klotho is a single-pass transmembrane protein with a long extracellular domain and short cytoplasmic tail that appears to modulate aging (2) . Klotho is expressed the highest in the kidney, suggesting that CKD might be a state of Klotho deficiency (3) . Klotho suppresses 1α-hydroxylase in the kidney to regulate calcium metabolism and participates in the regulation of parathyroid hormone (PTH) synthesis in parathyroid glands by fibroblast growth factor 23 (FGF23) (4, 5) . Klotho has not been extensively studied in the literature, especially in peritoneal dialysis (PD) and nonhemodialysis (HD) patients.
Objectives
Due to lack of data in Indian chronic renal failure patients regarding the relevance of Klotho, this crosssectional study was undertaken at a tertiary care centre to determine the sKlotho levels in chronic renal failure individuals and its correlation with various biochemical parameters involved in calcium phosphate homeostasis and echocardiographic findings. Diabetes therapies were associated with either a reduced or increased risk of cancer. There are continuous discussions about a possible protective action of metformin. In fact, metformin, a commonly consumed anti-diabetic medication has an ameliorative impact on some cancers by direct (preventing cell growth and apoptosis) and indirect (increasing insulin sensitivity) effects. Observational reports have suggested which metformin reduces the incidence of few common cancers. In general, metformin is an extensively recommended anti-diabetic medication with a recognized ability coupled with a satisfactory and safety profile and inexpensive. This review article considers reduction and protective abilities of metformin on cancers especially prostate, liver, breast, lung, and colon cancer. Introduction 1,1-dimethylbiguanide hydrochloride has known metformin, marketed under the trade name 'Glucophage' among others, is an oral glucose-lowering drug. In fact, in the early 20th century it was mentioned to lower blood glucose concentrations in animals, however it was not until the 1950s that Jean Sterne examined metformin and subsequently developed 'Glucophage' (1) . In other words, metformin is the most recommended oral drug with antihyperglycemic properties and is intended the first choice for treatment recently identified type II diabetes by several expert diabetes institutes (2) . In addition, with nearly 50 years of collected worldwide medical experience, metformin is mostly considered as safe with the most common side effects being gastrointestinal in nature such as nausea, diarrhea, and to the lowest amount, vomiting. In the same way, in comparison with most other drugs consumed to treat T2DM, metformin does not produce weight gain, and is commonly related to
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Patients and Methods
Study population
A cross-sectional study was conducted in 80 CKD patients (58 M/22 F) with a mean age of 54.21 ± 14.08years (25-90 years). They included 55 CKD stage 5D (CKD-5D) patients on HD (CKD-HD), 10 CKD-5D patients on PD (CKD-PD) and 15 CKD stage 3-4 patients not on dialysis (CKD-ND). The study population comprised of patients attending the dialysis and outpatient units at Madras medical mission hospital, Chennai. There were no exclusion criteria. Informed written consent was obtained from all the patients. We collected the following data from these patients: presence of diabetes mellitus and/ or hypertension, residual renal function (urine mL/d), vintage and frequency of HD. HD was conducted thrice a week using polysulfone membrane, with surface area 1.3/m 2 , 1.7/m 2 and 1.8/m 2 depending upon the body size. We looked at other comorbidities, such as previous cardiovascular disease, type of diet (vegetarian/nonvegetarian), serum calcium, phosphorous, 25(OH) vitamin D, intact PTH (iPTH), 2-dimensional echocardiography (to detect concentric left ventricular hypertrophy), calcification of aortic and mitral valve, left ventricular mass index (g/m 2 ), interventricular septal thickness (mm), and posterior wall thickness (mm). Blood samples were drawn after overnight fasting, centrifuged for 15 minutes at 2700 rpm, separated and frozen at -70°C. Serum Klotho levels in the serum were analyzed using a klotho ELISA kit, which was put to a run analyser at once after collecting all the samples. FGF23 (pg/mL) levels were also obtained from a 12-hour fasting serum sample using ELISA kit by Immutopics and relationships were analyzed.
Ethical issues
The research followed the Tenets of the Declaration of Helsinki. Ethical clearance was obtained from the institutional ethical committee. Informed written consent was obtained from all the study participants.
Statistical analysis
Statistical analysis was done using SPSS statistical software version 20.0 (IBM Corporation, Armonk, NY, USA). Independent samples t test was used to compare means. To look at correlations, we used Spearman's and Pearson's correlation methods.
Results
Clinical and demographic details of the patients are given in Table 1 . The measured sKlotho levels was <1 ng/mL in 74 (92.5 %) patients, 1-10 ng/ mL in three (3.75 %) patients and > 370 ng/mL in three (3.75%) patients. Serum Klotho was undetectable in 31 (38.75%) patients. Serum Klotho in CKD-HD patients ranged from 0 to 374.36 ng/mL with a mean of 13.76 ± 4.3 ng/mL. In continuous ambulatory PD patients, sKlotho levels ranged from 0 to 374.36 ng/ mL, with a mean of 37.58 ± 6.56 ng/mL (median: 0.0087 ng/mL). In the CKD-ND patients, sKlotho ranged from 0 to 7.01 ng/mL, with a mean of 0.73 ± 0.01 ng/mL (median; 0.1687 ng/mL). We observed very high sKlotho levels in three dialysis patients (2 HD and 1 PD) of 374.36 ng/ mL, 374.26 ng/mL and 374.36 ng/mL respectively who also had corresponding FGF-23 levels of 2423.2 pg/mL, 1164.2 pg/mL and 2423 pg/mL respectively. On plotting the sKlotho levels graphically, the data was positively skewed due to three high values. The Pearson's correlation between Klotho and FGF-23 serum levels was strongly positive (r = 0.853, P < 0.001) but the scatterplot showed skewed and heteroscedastic data as shown in Figure 1 . The correlation analysis was repeated.
After excluding four patients with high Klotho levels (>5 ng/mL), the resultant scatterplot is shown in Figure 2 (r = 0.310, P = 0.006). On excluding zero values in Klotho, Pearson's correlation showed a strong association with FGF 23 (r = 0.862, P = 0.007).
On further analysis using the independent samples t-test, these patients were found to have high FGF-23 (P < 0.001), high phosphorous (P = 0.001) and low vitamin D3 levels (P = 0.075). There was no statistically significant association of iPTH and left ventricular mass index (P = 0.60; Table 2 ). Ten patients expired in the eight months following the Klotho and FGF-23 measurement. Their mean FGF-23 and sKlotho levels were 275.28 ± 81.5 pg/mL and 0.026 ± 0.057 ng /mL, respectively.
Moreover, there was a significant association of left ventricular mass index with FGF-23 (r=0.308, P = 0.005) and sKlotho (r=-0.23, P = 0.045) (Spearman's correlation). Left ventricular mass index (LVMI) were classified into normal and abnormal by considering a cut off 96 for women and 116 for men (6) . A binomial regression was conducted to detect the effects of significantly correlated factors like FGF-23 and Klotho on LVMI. Out of two predictor variables, higher FGF-23 levels were significantly associated with abnormal LVMI (odds: 1.005, P = 0.031).
Discussion
Klotho was originally discovered as an anti-aging factor, but the functional role of Klotho is still a controversial issue (7) . Several factors, including phosphate and vitamin D, can regulate the production of both FGF23 and Klotho and influence their functions (8) . Recently, there has been experimental evidence to suggest that supplemental alpha klotho slows down the progression of CKD and has been tried in the treatment of acute kidney injury (9) . In our study, a strong, positive correlation was found between sKlotho and FGF23 levels in CKD patients. Pathologically, increased FGF23 levels may increase the Klotho gene expression, and therefore, sKlotho expression may have increased in our patients because of an increase in FGF23 levels. Recently Inci et al have studied 109 diabetic nephropathy patients and have found a positive correlation between FGF23 and sKlotho (10) . Klotho levels are decreased in CKD, but there is paucity of data on normal levels and range in literature. Buiten et al studied 127 HD patients, reporting a median sKlotho of 0.46 ng/mL, ranging from 0.35 ng/mL to 0.62 ng/mL (11) . In another study of 131 CKD patients, wherein sKlotho was measured by ELISA showed a range from 0.163.9 ng/ mL to 0.2123 ng/mL, with a median of 0.759 ng/mL (12) . Our study showed marked variation in the sKlotho values ranging from a minimum of 0 to a maximum of 374.36 ng/mL. Two CKD-HD patients and one CKD-PD patient had sKlotho levels > 370 ng/mL with corresponding high FGF-23 levels while such high values have not yet been reported in literature. All these three young patients underwent renal transplantation. One had a severe antibody mediated rejection (donor, mother) and the other two had graft thrombosis (donors; wife and father). They all had early graft loss within one month after initial good functioning. Hence, the role of Klotho and FGF-23 in this which again requires further clarification in future studies.
Serum Klotho has emerged as a powerful player in calcium-phosphate homeostasis, contributing to the high burden of cardiovascular disease (CVD) in CKD patients. Disorders of mineral homeostasis, as well as CVD develop in the early stages of CKD. Therefore, patients with ESRD have been exposed to an environment predisposing to vascular calcifications for a prolonged period of time. In our study, high sKlotho level was associated with high FGF-23, high phosphate and low vitamin D3 levels. Moreover, the role of sKlotho in the development of atherosclerotic disease in dialysis patients might be overshadowed by a large amount of other pathophysiological stimuli for CVD prevalent in these patients, such as smoking, obesity, diabetes and hypertension among others (11) .
As reported by previous studies, our study also reported an association between FGF-23 and LV mass index (13) (14) (15) . A majority of our patients had a high left ventricular mass index (mean: 122.5 ± 22.74 g/m 2 ), compared to previously established references for healthy men and women, which is not surprising in view of their CKD and elevated FGF-23 levels (16, 17) . Our study mainly looked at the sKlotho and FGF-23 levels in Indian CKD patients and correlation with various biochemical parameters.
Conclusion
Klotho deficiency occurs early in CKD, starting from pre-dialysis population. sKlotho levels show significant positive correlation with FGF23 levels in HD and PD patients. Young dialysis patients can have very high sKlotho levels of greater than 350ng/mL. These patients also had high FGF23 levels and may be more prone to cardiovascular complications, which requires clarification from further studies.
Limitations of the study
The limitations of our study are the lack of longitudinal estimation of sKlotho levels and small sample size.
